![]() |
市場調查報告書
商品編碼
1930128
尿失禁治療器材市場規模、佔有率、成長及全球產業分析:按類型、應用和地區劃分的洞察,2026-2034Urinary Incontinence Devices Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034 |
||||||
預計未來十年,全球尿失禁治療器材市場將穩定成長,這主要得益於公眾意識的提高、技術創新以及慢性病發病率的上升。根據 Fortune Business Insights 預測,該市場規模預計在 2025 年達到 45.3 億美元,2026 年將成長至 47 億美元,到 2034 年將達到 74.8 億美元,預測期內複合年增長率 (CAGR) 為 6.0%。北美地區將在 2025 年佔市場主導地位,市場佔有率將達到 42.5%,這反映了該地區先進的醫療保健基礎設施、有利的報銷政策以及積極的技術應用。
尿失禁護理裝置有助於預防尿液滲漏,提高舒適度,增強行動能力和獨立性,尤其對老年人而言。由於糖尿病、肥胖、泌尿道感染和神經系統疾病等疾病的盛行率不斷上升,全球對這些裝置的需求正在增加。例如,根據ScienceDirect發布的2025年數據,約有40%的歐洲人口患有尿失禁。包括Coloplast A/S、ConvaTec和Essity Actiebolag在內的領先企業正積極投入研發,致力於開發旨在改善病患照護的創新先進產品。
市場動態
成長驅動因素
急性和慢性疾病發生率的上升以及人口老化是市場成長的關鍵驅動因素。根據美國國家生物技術資訊中心 (NCBI) (2025) 的數據,全球尿失禁盛行率約為 32.4%,凸顯了對有效解決方案的廣泛需求。公眾意識的提高、社會歧視的減少以及更完善的醫保報銷政策正在進一步推動這些產品的普及。預計到 2030 年,全球六分之一的人口將超過 60 歲,這將支撐對這些醫療器材的長期需求。
限制因子
在巴西、中國和印度等發展中國家,有限的診斷能力和健保報銷政策制約了市場成長。患者就診較晚以及缺乏慢性病方面的臨床專業知識會導致診斷和治療延誤。例如,巴西的公共醫療體係不涵蓋急迫性尿失禁的藥物治療,限制了該地區病患獲得先進醫療器材的機會。
機會
可吸收和不可吸收產品(智慧感測器、行動應用程式、非侵入式神經調節設備等)的技術創新正在重塑市場格局。例如,UroMems公司於2025年2月宣布,接受其UroActive智慧植入物治療的女性患者達到了六個月的主要終點,證明了其臨床療效。這些進展為大型公司提供了拓展產品組合、滿足患者未被滿足的需求的機會。
挑戰
設備成本高昂,尤其是在新興市場,是其廣泛應用的一大障礙。尿失禁吊帶的價格從10美元到超過10,000美元不等,限制了患者的取得途徑。其他挑戰包括手術風險、器械故障、監管障礙以及來自行為療法和藥物療法等替代療法的競爭。
市場趨勢
一個顯著的趨勢是向微創手術的轉變,其驅動因素是恢復時間更短、疼痛更輕、住院時間更短。中段尿道吊帶和機器人輔助平台等技術正日益受到關注。根據國際尿控協會 (ICS) 2024 年的一項研究,中段尿道吊帶植入術後一年的再次手術率僅為 0.8%,五年的再次手術率僅為 2.7%,這表明治療效果和患者滿意度均有所提高。
依產品類型
市場分為吸收性產品和非吸收性產品。預計到 2026 年,吸收性產品(包括內褲、三角褲、護墊和床墊保護墊)將佔市場佔有率的 67.02%。非吸收性產品包括吊帶、導尿管、尿道插入物、刺激裝置和引流袋。
性別
由於女性尿失禁的高發生率,女性市場將在 2026 年佔主導地位,市場佔有率將達到 64.89%。根據 Phoenix Physical Therapy 2025 年的數據,美國 18 歲以上女性中,四分之一患有某種形式的尿失禁。預計男性市場在預測期內的複合年增長率將達到 4.9%。
按應用
由於其便利性和衛生優勢,一次性尿失禁產品將在 2026 年佔市場主導地位,市場佔有率將達到 58.3%。可重複使用產品預計將以 5.4% 的複合年增長率成長。
依最終使用者劃分
家庭醫療保健將在 2025 年佔市場主導地位,預計到 2026 年將佔 44.47% 的市場佔有率,這主要得益於患者對家庭護理的偏好以及充足的報銷政策。醫院和門診手術中心 (ASC) 預計將以 5.7% 的複合年增長率成長。
The global urinary incontinence devices market is poised for steady growth in the coming decade, driven by rising awareness, technological innovations, and increasing prevalence of chronic conditions. According to Fortune Business Insights, the market was valued at USD 4.53 billion in 2025 and is projected to grow to USD 4.7 billion in 2026, eventually reaching USD 7.48 billion by 2034, representing a CAGR of 6.0% during the forecast period. In 2025, North America dominated the market with a 42.5% share, reflecting the region's advanced healthcare infrastructure, favorable reimbursement policies, and strong technological adoption.
Urinary incontinence devices help prevent urine leakage, improve comfort, and enhance mobility and independence, particularly among the aging population. The rising prevalence of conditions such as diabetes, obesity, urinary tract infections, and neurological disorders is increasing the demand for these devices globally. For example, as per 2025 data published by ScienceDirect, approximately 40% of the population in Europe suffers from urinary incontinence. Key players including Coloplast A/S, Convatec Inc., and Essity Aktiebolag are actively focusing on R&D initiatives to develop innovative and technologically advanced products to enhance patient care.
Market Dynamics
Drivers
The growing incidence of acute and chronic diseases, coupled with an aging population, is a major driver of market growth. According to the NCBI (2025), the global prevalence of urinary incontinence was around 32.4%, highlighting the widespread need for effective solutions. Rising awareness, reduced stigma, and better reimbursement policies further encourage adoption. By 2030, one in six people globally is expected to be aged 60 or above, supporting the long-term demand for these devices.
Restraints
Market growth is constrained by limited diagnosis and reimbursement policies in developing nations, particularly in Brazil, China, and India. Delayed referrals and a lack of clinical expertise in chronic conditions result in postponed diagnosis and treatment. For instance, the Brazilian Public Health System does not cover pharmacotherapy for urge urinary incontinence, limiting access to advanced devices in the region.
Opportunities
Technological innovations in absorbent and non-absorbent products, including smart sensors, mobile apps, and non-invasive neuromodulation devices, are reshaping the market. For example, in February 2025, UroMems announced that female patients treated with UroActive Smart Implants successfully reached six-month primary endpoints, demonstrating clinical effectiveness. These advancements provide opportunities for key players to expand their portfolios and address unmet patient needs.
Challenges
High device costs hinder adoption, especially in emerging economies. Urinary incontinence slings range from USD 10 to over USD 10,000, limiting patient access. Additional challenges include surgical risks, device failures, regulatory hurdles, and competition from alternative treatments like behavioral therapy or pharmacological options.
Market Trends
A notable trend is the shift toward minimally invasive surgeries, driven by faster recovery, reduced pain, and shorter hospital stays. Technologies such as mid-urethral slings and robotic-assisted platforms are gaining traction. According to a 2024 study by the International Continence Society, mid-urethral sling insertions showed reoperation rates of only 0.8% at one year and 2.7% at five years, highlighting improved outcomes and patient satisfaction.
By Product Type
The market is segmented into absorbents and non-absorbents, with absorbents-including underwear, briefs, pads, and bed protectors-dominating 67.02% of the market in 2026. Non-absorbent products include slings, catheters, urethral inserts, stimulation devices, and drainage bags.
By Gender
The female segment dominated in 2026 with a 64.89% share, due to higher prevalence rates among women. According to 2025 Phoenix Physical Therapy data, one in four women over 18 in the U.S. experiences some form of urinary incontinence. The male segment is projected to grow at a CAGR of 4.9% during the forecast period.
By Usage
The disposable segment led in 2026 with 58.3% share, driven by convenience and hygiene benefits. Reusable products are expected to grow at a CAGR of 5.4%.
By End User
Homecare settings dominated in 2025, with an anticipated 44.47% market share in 2026, due to patient preference for at-home treatment and adequate reimbursement policies. Hospitals and ASCs are projected to grow at a CAGR of 5.7%.
Competitive Landscape
The market is highly competitive, led by Essity Aktiebolag, Medtronic, Coloplast A/S, BD, Teleflex, and Johnson & Johnson, who focus on product innovation, regulatory approvals, and geographic expansion. Notable developments include:
Conclusion
The global urinary incontinence devices market is projected to grow from USD 4.53 billion in 2025 to USD 7.48 billion by 2034, driven by rising prevalence of chronic conditions, technological advancements, and homecare adoption. While challenges such as high device costs and limited reimbursement in emerging markets persist, innovations in minimally invasive devices, smart sensors, and patient-centric solutions are expected to significantly expand market penetration and improve patient outcomes worldwide.
Segmentation By Product Type, Gender, Usage, End User, and Region
By Product Type * Absorbents
By Gender * Male
By Usage * Reusable
By End User * Hospitals & ASCs
By Region * North America (By Product Type, Gender, Usage, End User, and Country)